Mirae Asset Global Investments
SPRY icon

Mirae Asset Global Investments’s ARS Pharmaceuticals SPRY Stock Holding History

Mirae Asset Global Investments’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.6K Sell
4,441
-715
-14% -$6.15K ﹤0.01% 1415
2026
Q1 		$41.4K Buy
5,156
+353
+7% +$3.38K ﹤0.01% 1327
2025
Q4 		$56K Buy
4,803
+982
+26% +$9.55K ﹤0.01% 1369
2025
Q3 		$38.4K Buy
3,821
+27
+0.7% +$387 ﹤0.01% 1385
2025
Q2 		$66.2K Buy
3,794
+542
+17% +$7.82K ﹤0.01% 1218
2025
Q1 		$40.6K Buy
3,252
+13
+0.4% +$156 ﹤0.01% 1275
2024
Q4 		$34.9K Sell
3,239
-267
-8% -$3.74K ﹤0.01% 1327
2024
Q3 		$50.2K Buy
3,506
+613
+21% +$7.29K ﹤0.01% 1304
2024
Q2 		$23.3K Buy
+2,893
New +$25.7K ﹤0.01% 1361
2024
Q1 		– Sell
-16,534
Closed -$90.6K – 2638
2023
Q4 		$90.6K Buy
16,534
+152
+0.9% +$666 ﹤0.01% 2481
2023
Q3 		$61.9K Buy
16,382
+102
+0.6% +$670 ﹤0.01% 2533
2023
Q2 		$109K Buy
+16,280
New +$109K ﹤0.01% 2483

Other funds holding SPRY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
PCML
Pavaki Capital Management LLC Pueblo, Colorado $287M AUM
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
ELI
Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.57% 1-Year Est. Return

Mirae Asset Global Investments's SPRY Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its ARS Pharmaceuticals (SPRY) stake by 14% in Q2 2026, selling an estimated $6.15K and leaving 4,441 shares worth $35.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1415.

Mirae Asset Global Investments first reported a position in SPRY in Q2 2023 and has held it in 12 quarters since. The position peaked at $109K in Q2 2023. 68 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Mirae Asset Global Investments held 4,441 shares of ARS Pharmaceuticals worth $35.6K as of Q2 2026.
  • Mirae Asset Global Investments sold 715 ARS Pharmaceuticals shares in Q2 2026, an estimated $6.15K.
  • ARS Pharmaceuticals made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1415 holding.
  • Mirae Asset Global Investments first reported a position in ARS Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • Mirae Asset Global Investments's ARS Pharmaceuticals position peaked at $109K in Q2 2023.
  • 68 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.